A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Active, not recruiting · Phase 3 · NCT06253221
Conditions: Cardiomyopathy, Hypertrophic
At a glance
- Research payments reported, 2025
- $2,392
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 44
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Mavacamten (drug), Placebo (drug)
- Dates
- Started 2024-04-17; completion 2031-03-28
- Results posted
- Not yet
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
From ClinicalTrials.gov, last updated 2025-12-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $2,392 in research payments for this study in 2025 (3 payments).
Products named: Camzyos
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jondavid Menteer, MD Pediatric Cardiology · Los Angeles, CA
- Erin V. Shea, M.D Pediatric Cardiology · Durham, NC
- Brian Feingold, MD, MS Pediatric Cardiology · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University Hospital, NC $1,020
- Children's Hosp of Los Angeles, CA $711
- UPMC Children's Hospital of Pittsburgh Clinical Labs PAthology Department $661
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.